MCS
BNTX icon

Metatron Capital SICAV’s BioNTech BNTX Stock Holding History

Metatron Capital SICAV’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$204K Buy
+792
New +$217K 0.19% 107

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Metatron Capital SICAV's BNTX Position: Q4 2021 in Review

Metatron Capital SICAV opened a new position in BioNTech (BNTX) in Q4 2021: 792 shares worth $204K. The stake represents 0.19% of the portfolio and ranks #107 among its holdings.

354 funds tracked by Wall St. Rank hold BNTX as of Q4 2021.

  • Metatron Capital SICAV held 792 shares of BioNTech worth $204K as of Q4 2021.
  • BioNTech was a new Metatron Capital SICAV position in Q4 2021.
  • BioNTech made up 0.19% of Metatron Capital SICAV's portfolio in Q4 2021, its #107 holding.
  • 354 funds tracked by Wall St. Rank held BioNTech as of Q4 2021.

Based on Metatron Capital SICAV's 13F filing for Q4 2021, filed 15 Feb 2022.